Thermo Fisher and Sanofi Partners for US Drug Manufacturing
Thermo Fisher Scientific announced an expansion plan with its strategic partnership with Sanofi that will enable additional US drug product manufacturing. The terms of...
EMA Recommendations to Secure Anti-D Immunoglobulins Supply
The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have issued recommendations through the Executive Steering Group on Shortages and Safety...
FDA Approves Oral Therapy for Treating Hereditary Angioedema
The US Food and Drug Administration (FDA) has approved the first on-demand oral therapy for the treatment of acute attacks of hereditary angioedema (HAE)...
WuXi Biologics and Virogen Bio partner to advance VG712
WuXi Biologics, which happens to be a leading global contract research, development, and manufacturing organization (CRDMO), on June 9, 2025, happened to announce a...
Construction of WuXi Biologics Microbial Manufacturing Site
WuXi Biologics, which happens to be a leading global contract research, development, and manufacturing organization (CRDMO), on June 9, 2025, went on to announce...
Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season
In a recent development, Sanofi is shipping Beyfortus – nirsevimab starting early Q3 of 2025 in order to ensure a very broad availability. Well...
Thermo Fischer Accelerator Drug Development an Ideal Choice
Thermo Fisher Scientific Inc., which happens to be the world leader in serving science, on the 16th of June, 2025 announced the findings of...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...